January 24–27, 2022
Hero background

Speakers

All speakers

Heather Petruzzi

View Public Profile

Heather M. Petruzzi is a Partner at WilmerHale, where she advises life sciences and medical device companies on complex intellectual property matters. She represents clients in post-grant proceedings before the Patent Trials and Appeal Board (PTAB), in IP litigation before district courts and at the Federal Circuit, and in patent prosecution before the United States Patent and Trademark Office (PTO), and she also provides counseling on IP strategy and due diligence.

PTAB and PTO: Ms. Petruzzi represents clients as lead counsel across a variety of technologies in strategic post-grant proceedings before the PTAB, including inter partes review (IPR). She also prosecutes strategic patent portfolios for universities, startups and large companies.

Litigation: Ms. Petruzzi represents pharmaceutical companies in ANDA litigation, medical device clients, and life sciences clients in district court. She handles pre-litigation investigations, discovery, claim construction, expert discovery, expert reports and depositions. She has experience coordinating global litigation and foreign opposition strategies for both pharmaceutical and medical device clients. Ms. Petruzzi also drafts briefs and prepares for oral argument before the Federal Circuit in appeals from the district court and the PTO.

Counseling, Policy and Corporate Advice: Ms. Petruzzi counsels clients on freedom to operate matters and drafts invalidity and non-infringement opinions. She also counsels clients on IP policy and pending legislation issues. She works with clients on licensing, IP sales and acquisitions, and performs due diligence analyses.

Ms. Petruzzi serves on the firm’s post-grant proceedings, life sciences and medical device working groups. She is also a member of the firm’s Hiring Committee.

Sessions with Heather Petruzzi

01:00 PM EST
January 27, 2022

Life Sciences and IPR: Orange Book & Biologic Patents at the PTAB

The USPTO has recently released a third report providing data on post-grant petitions filed at the PTAB against Orange Book and biologic patents.  Although the report shows that such petitions represent only a small number of the petitions filed at the PTAB, namely 4% challenging Orange Book patents, and 2% challenging biologic patents, these IPRs challenge patents of high value. …

Stephanie Schonewald, PhD
Sharon Crane
Heather Petruzzi